Inclusion criteria | |
Males and females 20–85 years of age | |
Patients who have not started opioid therapy | |
Patients who will commence opioid therapy for cancer pain | |
Patients capable of oral intake | |
Patients capable of reporting the patient-reported outcomes | |
Patients who are expected to stay in stable pathological condition during the observation period | |
Patients who are able to provide written consent to participate in this research, follow instructions during participation, undergo protocol-specified physical examinations and other examinations, and report their symptoms or events | |
Exclusion criteria | |
Patients with any contraindications listed on the package insert for magnesium oxide/naldemedine or with a history of hypersensitivity to any ingredients of these drugs | |
Patients with a serious gastrointestinal structural anomaly (e.g., mechanical ileus), a disease that influences intestinal transit (e.g., paralytic ileus, peritoneal dissemination, peritoneal cancer, uncontrolled hyper-/hypothyroidism), irritable bowel syndrome, inflammatory bowel disease (e.g., ulcerative colitis, Crohn disease), active diverticular disease, pelvic disorders that cause constipation (e.g., uterine prolapse, rectal prolapse, myoma of the uterus that influences defecation), or patients whom the doctor decides have conditions with serious influence on gastrointestinal function (e.g., difficulty with oral intake), even if the aforementioned diseases are cured | |
Breastfeeding women or women with possible pregnancy | |
Patients who have undergone a surgery or a treatment that influences gastrointestinal function (e.g., nerve block) within 28 days before the enrollment day or patients planning to undergo go such surgery or treatment during the observation period |